

U.S. National Library of Medicine National Center for Biotechnology Information **NLM Citation:** Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-. Miglustat. [Updated 2020 Apr 20]. **Bookshelf URL:** https://www.ncbi.nlm.nih.gov/books/



Miglustat

Revised: April 20, 2020.

CASRN: 72599-27-0



Drug Levels and Effects

Summary of Use during Lactation

No published experience exists with miglustat during breastfeeding. Because of the lack of information and its side effect profile, most sources consider breastfeeding to be contraindicated during maternal miglustat therapy.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

Alglucerase, Imiglucerase, Taliglucerase Alfa

Substance Identification

Substance Name

Miglustat

CAS Registry Number

72599-27-0

Drug Class

Breast Feeding Lactation Enzyme Inhibitors Glycoside Hydrolase Inhibitors